Peter S. Knight - Aug 29, 2022 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role: Director
Signature: /s/ Wilhelm E. Liebmann, as attorney-in-fact for Peter S. Knight
Stock symbol: BIAF
Transactions as of: Aug 29, 2022
Transactions value $: $0
Form type: 3
Date filed: 12/5/2022, 03:09 PM
Next filing: Dec 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BIAF	Common Stock, par value $0.007						14.3K	Aug 29, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BIAF	Stock Option (right to buy)							Aug 29, 2022	Common Stock	7.14K	$7.70	Direct	F1, F2
holding	BIAF	Stock Option (right to buy)							Aug 29, 2022	Common Stock	7.14K	$7.70	Direct	F1, F3
holding	BIAF	Stock Option (right to buy)							Aug 29, 2022	Common Stock	7.14K	$7.70	Direct	F1, F4
holding	BIAF	Stock Option (right to buy)							Aug 29, 2022	Common Stock	7.14K	$4.20	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2	Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the Issuer's 2014 Equity Incentive Plan (the "EIP") on May 7, 2018. This option vested in 12 monthly installments beginning on June 7, 2018 and is fully vested and exercisable as of the date of this report.
F3	Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on July 29, 2019. This option vested in 12 monthly installments beginning on August 29, 2019 and is fully vested and exercisable as of the date of this report.
F4	Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on July 27, 2020. This option vested in 12 monthly installments beginning on August 27, 2020 and is fully vested and exercisable as of the date of this report.
F5	Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on December 16, 2021. On January 16, 2022, this option began vesting in 12 monthly installments, the first 11 of which are of 595 shares of Common Stock and the last of which is of the remaining 597 shares of Common Stock, subject to Mr. Knight's continuous service to the Issuer through each vesting date. As of the date of this report, 4,760 shares of Common Stock underlying this option have vested. The remaining unvested shares of Common Stock will vest immediately prior to the closing of the IPO on September 6, 2022.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Peter S. Knight)